Early investors could stand to turn every $5,000 invested into $55,000 – or more. Let me explain why in the short video below...
Watch the video now – or read on to discover the 5 shocking reason the “War on Cancer” may finally be over.
The end of cancer could become a reality sooner than anyone expected.
For decades, cancer patients were forced to choose between some combination of surgery, chemotherapy or radiation treatments.
But now an elite team of medical researchers, scientists and oncologists at the world-renowned University of Minnesota Cancer Center – led by Dr. Jeffery Miller, one of the world’s top 5 cancer researchers – has cracked the code.
This group has discovered a way to use your body’s “Natural Killer” cells to attack and destroy cancer cells and tumors from within.
I want exclusive access to your forecasts and recommendations, so I know what's coming ...
This breakthrough is one of the most exciting developments in the history of cancer research — and it could save millions of lives and make a cancer diagnosis something akin to getting the flu.
The company bringing this breakthrough to cancer patients across America – GT Biopharma (GTBP) – has full patent and license to this new therapy...guaranteeing the company a deadlock on this proprietary, cancer-fighting technology for years to come.
Scroll down to read the 5 shocking reasons the “War on Cancer” may finally be over or click here to view free bonus offer.
5 Disruptive Reasons Why Investors Could Triple their Money Thanks to this Cancer Breakthrough
This breakthrough involves a revolutionary targeted therapy that destroys cancer cells. It’s a new drug that trains the body’s own immune system to kill cancer cells while leaving healthy cells alone.
For more than 20 years, scientists have searched for a way to use your body’s immune system as the ultimate weapon for conquering cancer.
Now that dream may finally be coming true – a dream that could mean ...
At last, an elite team of medical researchers, scientists and oncologists at the University of Minnesota – led by Dr. Jeffrey Miller, one of the top 5 cancer researchers in the world – has cracked the code.
Biotech companies that specialize in immune-oncology can generate incredible wealth in a remarkably short period of time.
Every year, the big drug companies lose billions of dollars to generic versions. Thus many of them are on the hunt for smaller companies to partner with that have done all the research on new drugs.
One recent partnership sent shares of Affimed NV (Nasdaq: AFMD) through the roof.
In August, Affirmed announced that it would receive $96 million upfront in committed funding – with the potential for up to $5 billion more – from biotech giant Genentech.
This collaboration will be focused on developing cancer therapies using Affirmed’s expertise in Natural Killer (NK) cell engager-based immunotherapy.
The market reaction to this collaboration was swift – and significant:
Shares of Affimed NV (Nasdaq: AFMD) soared from $1.60 to $7.35 in less than 48 hours – a staggering gain of more than 350%!
Affirmed is one of just two companies in the world that have NK inhibitor technologies...and the other is GT Biopharma (GTBP).
There is also a strong possibility that GT Biopharma (GTBP) could be targeted for acquisition by any number of larger drug companies – which could put upward pressure on its stock price.
Investors have already seen this take place several times – in just the past two years – with staggering buyouts of smaller companies by “Big Pharma” including:
Companies with impressive immune-oncology assets can attract the attention of Big Pharma in a very short period of time. The possibility of a potential buyout can be enough, in some cases, to send a company’s share price soaring.
I’m convinced that GT Biopharma (GTBP) right now has the same type of explosive potential demonstrated by other companies that have been acquisition targets.
A potential buyout scenario could help investors collect gains of 1,000% -- or more – in less than 12 months.
Early research in this field used what is called CAR-T therapy.
This technology used genetically modified T-cells (a crucial part of your body’s immune system) to fight cancer.
While there have been some successes with this approach, it does come with a number of drawbacks:
It requires invasive surgery to remove and replace the T-cells...
At $750,000 per patient, it’s prohibitively expensive...
Patients have to adhere to a strict regimen of toxic anti-viral drugs...
Worst of all, the cancer often recurs within the first 6 to 12 months.
GT Biopharma’s breakthrough – developed in conjunction with the elite team from the University of Minnesota – is completely different and vastly superior to CAR-T therapy.
You see, one of the biggest challenges when it comes to treating cancer is that cancer cells have the frightening ability to send false signals to your immune system. These signals often trick your immune system into ignoring the cancer cells until it’s too late.
However, this new therapy taps into the power of your body’s Natural Killer Cells (NK Cells) – your immune system’s most powerful weapon against cancer and other diseases.
And with the help of GT Biopharma’s (GTBP) drug, they are able to see past the cancer cells’ false signals, locate cancerous cells and wipe them out.
In other words, GT Biopharma could be on the verge of a disruptive, life-saving advance in cancer treatment. And as the results of clinical testing for this “next generation” therapy prove promising, early investors in the company could see significant gains.
Investors all over the world are paying close attention to the potential for a breakthrough in our long-running war on cancer.
Some of the world’s most famous investors are not only watching for new developments...they have also spotted an opportunity to collect potentially massive profits as new therapies are researched.
The list of famous investors backing new cancer therapies is an impressive one, and it includes...
* Microsoft founder Bill Gates, who has invested $40 million via his Bill & Melinda Gates Foundation in immunotherapy. Gates has said that, “Our hope is that it’s this immunotherapy research for cancer that will give us the insights to control all of these infectious diseases, which would be a huge victory for humanity, and, hopefully, also a significant market for life sciences.”
* Facebook co-founder Sean Parker, who together with his wife Alexandra has donated $250 million to cancer immunotherapy research to six cancer centers nationwide.
* Amazon CEO Jeff Bezos, whose venture fund Bezos Expeditions was an early investor back in 2014 in Juno Therapeutics – the biotech startup that was acquired by Celgene January 2018 $9 billion.
Investors have been cashing in – to the tune of double and triple digit returns – with select biotech stocks over the past two years.
This is precisely the type of potential with a relatively unknown company right now – GT Biopharma (GTBP), which could potentially follow in the footsteps of biotech blockbusters such as...
* Iovance Biotherapeutics, Inc. (IOVA) has more than tripled – climbing 216.5% over the past 15 months...
* Agios Pharmaceuticals, Inc. (AGIO) has helped investors double their money over the past two years, soaring 106.5%...
* Bluebird Bio, Inc. (BLUE) has more than tripled over the last two years – climbing 223.1% since October 2016.
* And Atara Biotherapeutics, Inc. (ATRA) skyrocketed 50% in just 2 days in January 2018 – and is up 156% year-to-date – on the basis of FDA approval of an ongoing clinical study.
GT Biopharma, Inc. (GTBP) now offers similar potential for early investors thanks to the company’s breakthrough cancer therapy – with potential 36-month profits as high as 1,000%.
Bottom Line: This is a Strong Buy for My Subscribers
I believe that GT Biopharma (GTBP) is a terrific investment opportunity that gives you the chance to invest in something that could save lives and potentially turn every $5,000 invested into $55,000 over the next 36 months.
I’ve talked to management. I’ve done my research. I’ve issued a buy signal to my subscribers. And I believe now is the time to buy, while GT Biopharma (GTBP) is still under the radar.
I’ve prepared a comprehensive Special Report to tell you even more about GT Biopharma (GTBP). It’s called Killing Cancer: How a Biotech Breakthrough Could Bring 1000% Profits – and a copy is yours FREE when you accept a risk-free trial subscription to my newsletter, Strategic Investment.
Strategic Investment brings you profitable investment recommendations...regular updates on the economy and the markets...and forecasts to help you prepare to prosper in the months ahead.
Plus, you’ll receive breaking news and buy, hold and sell updates about GT Biopharma (GTBP).
My readers have been able to more than double their money by investing in disruptive companies before they exploded in value, such as:
I predicted Donald Trump’s victory four months before the election and, with that in mind, made a surprising currency recommendation. Soon after the election, investors who followed my advice could have locked in profits of 4,100%.
Scythian Biosciences, a company developing a cannabinoid-based drug treatment for concussion, soared 860% after my prediction.
In November 2017, with cryptocurrencies making headlines, I saw a fast profit opportunity with RIOT Blockchain. Within a month, it soared from $8.06 to $40.75, for a 405.5% gain.
But I have to tell you...Strategic Investment is about much, much more than just winning stock trades. A subscription to Strategic Investment gives you a direct line to my 30-year history of accurate predictions...big picture foresight...and geopolitical connections.
For more information about Strategic Investment, simply click the button below. Or, to subscribe now and claim your FREE Special Report, call Toll-Free 1-877-524-9298.
James Dale Davidson, Editor
What YOU Should Consider Now
Visionary investor James Dale Davidson has more than three decades of experience helping investors build wealth by providing accurate “big picture” forecasts and discovering hidden profit opportunities before Wall Street catches on.
Today, James sees a significant opportunity in this potentially disruptive new cancer therapy that could represent the next frontier for cancer treatments.
IMPORTANT NOTICE AND DISCLAIMER:All investments are subject to risk, which must be considered on an individual basis before making any investment decision. Strategic Investment is the publisher of these materials and is not responsible for errors and omissions. This publication is intended solely for information and educational purposes and is not to be construed, under any circumstances, as an offer to buy or sell, or a solicitation to buy or sell or trade, or as a personal recommendation to buy or sell or trade in any securities or commodities named within these materials. These materials are a paid advertisement. Information gathered to create these materials is from sources believed to be reliable but is in no way guaranteed. Furthermore, you cannot be assured that you will profit or that any losses can or will be limited. It is important to know that no guarantee of any kind is implied or possible where projections of future conditions in the markets are attempted. Hypothetical or simulated performance results have certain inherent limitations as to liquidity and execution, among other variables. All readers should consult their own personal investment adviser before making an investment decision. Investing in securities is highly speculative and carries a great deal of risk, especially as to newer companies with comparatively short operating histories and limited earnings. This report contains projections regarding future operating results, which are forward-looking statements. Those projections were derived from sources that have not been verified independently. All forward-looking statements are believed to have a reasonable basis, but are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Those projections should not be considered a comprehensive representation of the featured company’s future performance. Strategic Investment is a paid circulation newsletter and is not a financial analyst, investment advisor or broker/dealer. These materials are a solicitation for subscriptions for the newsletter and a paid promotional advertisement of GTBiopharma, Inc (OTC: GTBP). Strategic Investment expects to generate new subscriber revenue as a result of this advertisement. This paid advertisement includes a stock profile of GTBiopharma, Inc (GTBP). Strategic Investment assumes no obligation to provide any future views in support of the highlighted company. In an effort to enhance public awareness of GTBiopharma, Inc (GTBP) and its securities, provided third-party advertising agencies with a total campaign budget of approximately two million sixty-three thousand six hundred and thirty-four dollars to date to cover the costs associated with creating, printing and distribution of this advertisement and other elements of this campaign in an effort to build investor awareness. Strategic Investment was paid thirty thousand dollars as a research fee. In addition, Strategic Investment may generate new subscription revenue, the amount of which is unknown at this time, as a result of the distribution of these materials. The advertising agencies involved in the campaign relied on information provided by GTBiopharma, Inc (GTBP) and Strategic Investment. The advertising agencies will retain as their compensation any excess sums remaining in the total campaign budget after all expenses are paid. Readers should take this into consideration in evaluating the statements in these advertising materials. If successful, this advertisement will increase investor and market awareness, which may result in increased numbers of shareholders owning and trading the securities of GTBiopharma, Inc (GTBP), increased trading volumes, and possibly increased share price of the company’s securities. This advertisement, the advertising agencies and Strategic Investment do not purport to provide an analysis of any company’s financial position, operations or prospects, and this is not to be construed as a recommendation by GTBiopharma, Inc (GTBP) or as an offer to buy or sell any security or as investment advice. An offer to buy or sell can only be made with accompanying disclosure documents and only in states and provinces for which they are approved. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC filings. Investing in securities, particularly micro-cap securities such as GTBiopharma, Inc (GTBP), is inherently speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agencies and Strategic Investment cannot guarantee the accuracy or completeness of the information. The advertising agencies and Strategic Investment note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company’s products and services, the company’s ability to fund its capital requirements in the near term and long term, pricing pressures, etc. Strategic Investment is the publisher’s trademark. All trademarks used in this advertisement other than Strategic Investment are the property of their respective trademark holders and no endorsement by such owners of the contents of these materials is made or implied. The advertising agencies and Strategic Investment are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by them to any rights in any third-party trademarks. More information can be found on the GTBiopharma, Inc website at (www.GTBiopharma.com). As with any low-priced stock, investors should use only risk capital they are willing to lose or hold for long-term investing.